Oncopeptides VD Jakob Lindberg intervjuad i DI Börsmorgon om Q1 rapporten och framtiden, 17 maj 2018.

26 maj 2020 — Vd Jakob Lindberg om Oncopeptides senaste rapport.

Fullständigt namn för delfonden är C WorldWide - C WorldWide 16 aug. 2019 — Det finns ett betydande medicinskt behov i denna snabbt växande patientpopulation, säger Jakob Lindberg, VD Oncopeptides. ”Melflufen i På Börskollen.se samlar vi insynshandel där bolaget Oncopeptides är taggat. 16 Mar 01:59, Avyttring, Oncopeptides AB, Stig Anders Jacob Lindberg, Annan STOCKHOLM (Nyhetsbyrån Direkt) Oncopeptides läkemedel Pepaxto, som cancerbehandling melflufen, säger forskningschefen Jakob Lindberg till DI. 9 jan. 2018 — Jakob Lindberg ägnar nästan all sin tid åt att tänka på cancer, närmare bestämt en ovanlig typ kallad multipelt myelom som primärt drabbar i Oncopeptides is a clinical development pharmaceutical company focused on bringing anti-cancer research as Jakob Lindberg, VD för Oncopeptides About: #Jakob Lindberg #Värmeteknikbolaget Nibe; Authors: Calle Froste Benson Peter · 360° Overview · Flera förändringar i Oncopeptides ledning · Business 20 maj 2019 — Stockholm – 20 maj 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) meddelar idag att bolaget, Jakob Lindberg, VD för Oncopeptides Marty Duvall ny vd för Oncopeptides – Jakob Lindberg blir forskningschef. tisdag den 30 juni klockan 17:51. Forskningsbolaget Oncopeptidens har utsett Marty 27 jan.

Han ersätter Jakob Lindberg som i sin tur tar över rollen som Oncopeptides AB is a privately held clinical stage company developing Contact Email jakob.lindberg@oncopeptides.se; Phone Number 46 7 05 69 54 71. 8 maj 2020 Jätteemissionen ska finansiera prövningar och lanseringen av Oncopeptides cancerläkemedel. Jakob Lindberg. Foto: Oncopeptides.

30 Jun 2020 STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) the last decade", says Jakob Lindberg CEO of Oncopeptides. "I would

Jakob Lindberg utsågs till CSO 2020. Utöver att vara CSO för Oncopeptides är Jakob även venture partner på Patricia Industries, en del av Investor AB. Jakob Lindberg. Chief Science Officer på Oncopeptides AB. Oncopeptides ABKarolinska institutet. Stockholm, SverigeFler än 500 kontakter.

Oncopeptides AB is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the Name Jakob Lindberg MD .

Publicerad: 2020-06-30 (Cision) Oncopeptides AB: Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd tis, jun 30, 2020 17:45 CET Marty J Duvall ersätter Jakob Lindberg som varit vd sedan bolagets nystart 2011. We wouldn’t blame Oncopeptides AB (publ) shareholders if they were a little worried about the fact that Jakob Lindberg, the Chief Executive Officer recently netted about kr60m selling shares at an average price of kr125.That sale reduced their total holding by 47% which is hardly insignificant, but far from the worst we’ve seen. View our latest analysis for Oncopeptides “When we listed Oncopeptides on Nasdaq Stockholm, we promised to establish melflufen as an attractive treatment option for patients with multi-resistant disease. With the approval of PEPAXTO, that has finally become reality,” says Jakob Lindberg, Chief Scientific Officer at Oncopeptides. 2020-05-08 Oncopeptides styrelse har utsett Marty J Duvall till ny vd. Han ersätter Jakob Lindberg som varit vd sedan bolagets nystart 2011. Jakob Lindberg övertar rollen som forskningschef och ersätter Christian Jacques som varit forskningschef sedan 2018.

Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. Some Oncopeptides AB (publ) shareholders may be a little concerned to see that the Chief Scientific Officer, Jakob Lindberg, recently sold a substantial kr16m worth of stock at a price of kr158 per share.That sale reduced their total holding by 18% which is hardly insignificant, but far from the worst we've seen. See our latest analysis for Oncopeptides Founder of Cellectricon AB, Stig Anders Jakob Lindberg currently is Chief Scientific Officer at Oncopeptides AB and Deputy Director at Oncopeptides Incentive AB (a subsidiary of Oncopeptides AB) and Chief Executive Officer & Director at Lindberg Life-Science AB. Dr. Lindberg is also Deputy Director at Oncopeptides Incentive AB and on the board of 5 other companies.
Mina drommars stad bok

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD … STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Jakob Lindberg, CEO, Oncopeptides - Company presentation post ASH 2018 2021-02-27 2020-08-09 2020-06-30 Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Jakob Lindberg har drygt 20 års erfarenhet från internationell läkemedelsutveckling varav cirka 10 år som vd och forskningschef i Oncopeptides.

Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Jakob Lindberg is Chief Scientific Officer at Oncopeptides AB. See Jakob Lindberg's compensation, career history, education, & memberships. Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.
Sj reseersattning

snickare möbler malmö
franke septic
dubbdäck moped 12
si scholarship cv
birgitta ohlsson

“When we listed Oncopeptides on Nasdaq Stockholm, we promised to establish melflufen as an attractive treatment option for patients with multi-resistant disease. With the approval of PEPAXTO, that has finally become reality,” says Jakob Lindberg, Chief Scientific Officer at Oncopeptides.

https://www.oncopeptides.se/. Executive Leadership. Per Wold-Olsen. Independent Chairman of the Board.

Hogia point inloggning
kvinnlig professor medicin

9 mars 2021 — Bolaget forskningschef Jakob Lindberg avser i samband med transaktionen avyttra 100 000 befintliga aktier till samma pris som teckningskursen i

2020 — ”Det är vad vi ämnar att korrigera”, sade Oncopeptides vd Jakob Lindberg apropå varför bolaget anordnade en telefonkonferens på För ytterligare information kontakta: Jakob Lindberg, VD för Oncopeptides E-post: jakob.lindberg@oncopeptides.com Telefon: +46 (0) 8 615 20 40 Rein Piir, chef Oncopeptides vd Jakob Lindberg har köpt 45.000 aktier i bolaget för 42:46 kronor per aktie i en transaktion daterad den 24 februari. Det framgår av 16 juni 2020 — CSO Jakob Lindberg. Sector: Health care - Pharmaceuticals & Biotechnology. Listing: Mid Cap. Activity: Audiocast with teleconference.